

Tsuchiyama, T., Nakamoto, Y., Sakai, Y., Mukaida, N., Kaneko, S	Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation.	Cancer Sci.	99(10)	2075-2082	2008
Nakamoto Y, Mizukoshi E, Tsuji H, Sakai Y, Kitahara M, Arai K, Yamashita T, Yokoyama K, Mukaida N, Matsushima K, Matsui O and Kaneko S	Combined Therapy of Transcatheter Hepatic Arterial Embolization with Intratumoral Dendritic Cell Infusion for Hepatocellular Carcinoma; Clinical Safety.	Clin. Exp. Immunol.	147(2)	296-305	2007
Tsuchiyama T, Nakamoto Y, Sakai Y, Marukawa Y, Kitahara M, Mukaida N and Kaneko S	Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma.	J. Immunol.	178(1)	574-83	2007
Oishi N, Shilagardi K, Nakamoto Y, Honda M, Kaneko S and Murakami S	Hepatitis B virus X protein overcomes oncogenic RAS-induced senescence in human immortalized cells.	Cancer Sci.	98(10)	1540-8	2007

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, <u>Hotta H</u>	Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of Hepatitis C virus and anti-NS5A antibodies in pre-treatment sera.	Microbiol Immunol	51	471-482	2007
El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, <u>Hotta H.</u>	Sequence variation in the hepatitis C virus NS5A protein predicts clinical outcome of pegylated interferon/ ribavirin combination therapy.	Hepatology	48(1)	38-47	2008
Deng L, Adachi T, Kitayama K, Bungyoku Y, Kitazawa S, Ishido S, Shoji I, <u>Hotta H</u>	Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediat ed, caspase-3-dependent pathway.	J Virol	82(11)	10375-103 85	2008
Sasase N, Kim SR, Kim KI, Taniguchi M, Imoto S, Mita K, <u>Hotta H</u> , Shoji I, El-Shamy A, Kawada N, Kudo M, Hayashi Y.	Usefulness of new immuno-radiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral loads of serum HCV RNA genotype 1b.	Intervirology	51(Suppl 1)	70-75	2008

Inubushi S, Nagano-Fujii M, Kitayama K, Tanaka M, An C, Yokozaki H, Yamamura H, Nuriya H, Kohara M, Sada K, <u>Hotta H</u>	Hepatitis C virus NS5A protein interacts with and negatively regulates the non-receptor protein-tyrosine kinase Syk.	J Gen Virol	89(5)	1231-1242	2008
El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, <u>Hotta H</u> .	Sequence variation in the hepatitis C virus NS5A protein predicts clinical outcome of pegylated interferon/ ribavirin combination therapy.	Hepatology	48(1)	38-47	2008
Kim S R, Imoto S, Mita K, Taniguchi M, Sasase N, Muramatsu A, Kudo M, Kitai S, El-Shamy A, <u>Hotta H</u> , Hayashi Y.	Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum HCV RNA, genotype 1b, discontinued on attaining sustained virological response in week 16 after onset of acute pancreatitis.	Digestion	79(1)	36-39	2009
Kasai D, Adachi T, Deng L, Nagano-Fujii M, Sada K, Ikeda M, Kato N, Ide Y, Shoji I, <u>Hotta H</u> .	HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters.	J Hepatol	50	883-894,	2009
Bungyoku Y, Shoji I, Makine T, Adachi T, Hayashida K, Nagano-Fujii M, Ide Y, Deng L, <u>Hotta H</u> .	Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma.	J Gen Virol	90(7)	1681-1691,	2009
Amako Y, Sarkeshik A, <u>Hotta H</u> , Yates J 3rd, Siddiqui A.	Role of oxysterol binding protein in hepatitis C virus infection.	J Virol	83(18)	9237-9246,	2009

Mohd-Ismail NK, Deng L, Sukumaran SK, Yu VC, <u>Hotta H</u> , Tan YJ.	The hepatitis C virus core protein contains a BH3 domain that regulates apoptosis through specific interaction with human MCL-1.	J Virol	83(19)	9993-10006,	2009
Kim SR, Imoto S, Kudo M, Mita K, Taniguchi M, Kim KI, Sasase N, Shoji I, Nagano-Fujii M, El-Shamy A, <u>Hotta H</u> , Nagai T, Nagata Y, Hayashi Y.	Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics	Intervirology	53(1)	44-48	2010
Sasase N, Kim SR, Kudo M, Kim KI, Taniguchi M, Imoto S, Mita K, Hayashi Y, Shoji I, El-Shamy A, <u>Hotta H</u>	Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.	Intervirology	53(1)	49-54	2010
金守良, 井本勉, 婦木秀一, 金啓二, 谷口美幸, 長野基子, 堀田博, 勝二郁夫, 寒原芳浩, 前川陽子, 工藤正俊, 林祥剛	1b型高ウイルス量高齢者C型慢性肝炎に対するPEG IFN α -2b/リバビリン治療(併用療法)の検討.	肝臓	49(4)	145-152	2008
金守良, 井本勉, 三田敬二, 谷口美幸, 金啓二, 勝二郁夫, 長野基子, <u>堀田博</u>	1b型高ウイルスC型慢性肝炎のPEG-IFN+リバビリン併用療法(併用療法)無効例に対する二重濾過血漿交換療法(DFPP)+IFN- β 4週間連続投与の試み 早期ウイルス dynamicsを中心に.	肝臓	50(8)	470-472,	2009

別紙4

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
Aizaki H, <u>Suzuki T.</u>	RNA Replication of Hepatitis C Virus	Cheng RH, Miyamura T.	Structure-based Study of Viral Replication	World Scientific	Singapore	2008	151-172
<u>鈴木哲朗</u> 、 政木隆博、 相崎英樹	C型肝炎ウイルスの感染粒子形成機構	小柳義夫	ウイルス	日本ウイルス学会	東京	2008	199-206

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Suzuki T.</u> , Ishii K, Aizaki H, Wakita T.	Hepatitis C viral life cycle.	Adv Drug Deliv Rev	59	1200-1212	2007
<u>Suzuki T.</u> , Aizaki H, Murakami K, Shoji I, Wakita T.	Molecular biology of hepatitis C virus.	J Gastroenterol	42	411-23	2007
Shirakura M, Murakami K, Ichimura T, Suzuki R, Shimoji T, Fukuda K, Abe K, Sato S, Fukasawa M, Yamakawa Y, Nishijima M, Moriishi K, Matsuura Y, Wakita T, <u>Suzuki T.</u> , Howley PM, Miyamura T, Shoji I.	E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein.	J Virol	81	1174-1185	2007
Miyamoto H, Moriishi K, Moriya K, Murata S, Tanaka K, <u>Suzuki T.</u> , Miyamura T, Koike K, Matsuura Y.	Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein.	J Virol	81	1727-1735	2007

Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, Murata S, Tanaka K, Miyamura T, <u>Suzuki T</u> , Koike K, Matsuura Y.	Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis.	Proc Natl Acad Sci USA	104	1661-1666	2007
Ishii K, Iijima S, Kimura N, Lee YJ, Ageyama N, Yagi S, Yamaguchi K, Maki N, Mori K, Yoshizaki S, Machida S, <u>Suzuki T</u> , Iwata N, Sata T, Terao K, Miyamura T, Akari H.	GBV-B as a pleiotropic virus: distribution of GBV-B in extrahepatic tissues in vivo.	Microbes Infect	9	515-521	2007
Mizutani T, Endoh D, Shirato K, Shimizu H, Fukushi S, Saijo M, Sakai K, Kwang L, Ito M, Nerome R, Takasaki T, Ishii K, <u>Suzuki T</u> , Kurane I, Morikawa S, Nishimura H.	Rapid genome sequencing of RNA viruses.	Emerg Infect Dis	13	322-324	2007
Murayama A, Date T, Morikawa K, Akazawa D, Miyamoto M, Kaga M, Ishii K, <u>Suzuki T</u> , Kato T, Mizokami M, Wakita T..	The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells.	J Virol	81	8030-8040	2007
Inoue Y, Murakami K, Hmwe SS, Aizaki H, <u>Suzuki T</u> .	Transcriptomic comparison of human hepatoma Huh-7 cell clones with different hepatitis C virus replication efficiencies.	Jpn J Infect Dis	60	173-178	2007
Nitahara-Kasahara Y, Fukasawa M, Shinkai-Ouchi F, Sato S, <u>Suzuki T</u> , Murakami K, Wakita T, Hanada K, Miyamura T, Nishijima M.	Cellular vimentin content regulates the protein level of Hepatitis C virus core protein and the Hepatitis C virus production in cultured cells.	Virology	383	319-327	2008

Akazawa D, Date T, Morikawa K, Murayama A, Omi N, Takahashi H, Nakamura N, Ishii K, <u>Suzuki T</u> , Mizokami M, Mochizuki H, Wakita T.	Characterization of infectious hepatitis C virus from liver-derived cell lines.	Biochem Biophys Res Commun	377	747-751	2008
Masaki, T., Suzuki, R., Murakami, K., Aizaki, H., Ishii, K., Murayama, A., Date, T., Matsuura, Y., Miyamura, T., Wakita, T., <u>Suzuki, T.</u>	Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus production.	J Virol	82	7964-7976	2008
Ishii, K., Murakami, K., Hmwe, SS., Bin, Z., Li, J., Shirakura, M., Morikawa, K., Suzuki, R., Miyamura, T., Wakita, T., <u>Suzuki, T.</u>	Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins.	Biochem Biophys Res Commun	371	446-450	2008
Aizaki, H., Morikawa, K., Fukasawa, M., Hara, H., Inoue, Y., Tani, H., Saito, K., Nishijima, M., Hanada, K., Matsuura, Y., Lai, M.M., Miyamura, T., Wakita, T., <u>Suzuki, T.</u>	A Critical Role of Virion-Associated Cholesterol and Sphingolipid in Hepatitis C Virus Infection.	J Virol	82:	5715-5724	2008
Okamoto K., Mori Y., Komoda Y., Okamoto T., Okochi M., Takeda M., <u>Suzuki T.</u> , Moriishi K., Matsuura Y.	Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation.	J Virol	82:	8349-8361	2008

Okamoto T., Omori H., Kaname Y., Abe T., Nishimura Y., <u>Suzuki T.</u> , Miyamura T., Yoshimori T., Moriishi K., Matsuura Y.	A single amino acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication.	J Virol	82:	3480-3489	2008
Taguwa S, Okamoto T, Abe T, Mori Y, <u>Suzuki T</u> , Moriishi K, Matsuura Y.	Human Butyrate-Induced Transcript 1 Interacts with Hepatitis C Virus NS5A and Regulates Viral Replication.	J Virol	82	2631-2641	2008
Omata, K., Suzuki, R., Masaki, T., Miyamura, T., Satoh, T., <u>Suzuki, T.</u>	Identification and characterization of the human inhibitor of caspase-activated DNase gene promoter.	Apoptosis	13	929-937	2008
Murakami, K., Kimura, T., Osaki, M., Ishii, K., Miyamura, T., <u>Suzuki, T.</u> , Wakita, T., Shoji, I.	Virological characterization of HCV JFH-1 strain in lymphocytic cell lines.	J Gen Virol	89	1587-1592	2008
Murakami K, Inoue Y, Hmwe SS, Omata K, Hongo T, Ishii K, Yoshizaki S, Aizaki H, Matsuura T, Shoji I, Miyamura T, <u>Suzuki T.</u>	Dynamic behavior of hepatitis C virus quasispecies in a long-term culture of the three-dimensional radial-flow bioreactor system.	J Virol Methods.	148	174-181	2008
Hara H, Aizaki H, Matsuda M, Shinkai-Ouchi F, Inoue Y, Murakami K, Shoji I, Kawakami H, Matsuura Y, Lai MMC, Miyamura T, Wakita T, <u>Suzuki T</u>	Involvement of creatine kinase B in hepatitis C virus genome replication through interaction with the viral NS4A protein.	J Virol	83	5137-5147	2009
Suzuki, R., Moriishi, K., Fukuda, K., Shirakura, M., Ishii, K., Wakita, T., Miyamura, T., Matsuura, Y., <u>Suzuki, T</u>	Proteasomal turnover of hepatitis C virus core protein is regulated by two distinct mechanisms: ubiquitin-dependent and ubiquitin-independent but PA28gamma-dependent.	J Virol	83	2389-2392	2009

Kukihara H, Moriishi K, Taguwa S, Tani H, Abe T, Mori Y, Suzuki T, Fukuhara T, Taketomi A, Maehara Y, Matsuura Y	Human VAP-C negatively regulates hepatitis C virus propagation.	J Virol	83	7959-7969	2009
Tsutsumi T, Matsuda M, Aizaki H, Moriya K, Miyoshi H, Fujie H, Shintani Y, Yotsuyanagi H, Miyamura T, <u>Suzuki</u> <u>T</u> , Koike K.	Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperone, prohibitin, in cells expressing hepatitis C virus core protein.	Hepatology	50	378-386	2009
Taguwa S, Kambara H, Omori H, Tani H, Abe T, Mori Y, <u>Suzuki T</u> , Yoshimori T, Moriishi K, Matsuura Y.	Cochaperone activity of human butyrate-induced transcript 1 facilitates hepatitis C virus replication through an Hsp90-dependent pathway..	J Virol	83	10427-104 36	2009
Shimoji T, Murakami K, Sugiyama Y, Matsuda M, Inubushi S, Nasu J, Shirakura M, <u>Suzuki</u> <u>T</u> , Wakita T, Kishino T, Hotta H, Miyamura T, Shoji I	Identification of Annexin A1 as a novel substrate for E6AP-mediated ubiquitylation.	J Cell Biochem	16	1123-1135	2009
Murakami Y, Noguchi K, Yamagoe S, <u>Suzuki T</u> , Wakita T, Fukasawa H	Identification of bisindolylmaleimides and indolocarbazoles as inhibitors of HCV replication by tube-capture-RT-PCR.	Antiviral Res	83	112-117	2009
Moriya K, Miyoshi H, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Yotsuyanagi H, Moriishi K, Matsuura Y, <u>Suzuki</u> <u>T</u> , Miyamura T, Koike K	Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein: analysis using mouse model and cultured cells.	Am J Pathol	175	1515-1524	2009
Nitahara-Kasahara Y, Fukasawa M, Shinkai-Ouchi F,	Cellular vimentin content regulates the protein level of	Virology	383	319-327	2009

Sato S, <u>Suzuki T</u> , Murakami K, Wakita T, Hanada K, Miyamura T, Nishijima M.	Hepatitis C virus core protein and the Hepatitis C virus production in cultured cells.				
Saeed M, Suzuki R, Kondo M, Aizaki H, Kato T, Mizuochi T, Wakita T, Watanabe H, <u>Suzuki T</u>	Evaluation of hepatitis C virus core antigen assays in detecting recombinant viral antigens of various genotypes.	J Clin Microbiol	47	4141-4143	2009
Hmwe SS, Aizaki H, Date T, Murakami K, Ishii K, Miyamura T, Koike K, Wakita T, <u>Suzuki T</u>	Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.	Antiviral Res			In press

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
荒瀬康司 鈴木文孝 熊田博光	抗ウイルス療法の安全性と治療効果	岡上武 小俣政男 林紀夫 熊田博光	コンセンサス 肝疾患 2007	日本メデ イカルセ ンター	東京都	2007	110~115
鈴木文孝	B 型肝炎ウイルスの遺伝子変異と病態	熊田博光	B 型慢性肝炎のマネジメント(改訂版)	医薬ジャーナル社	大阪府	2007	18-29
鈴木文孝 熊田博光	B型慢性肝炎	菅野健太郎 上西紀夫 井廻道夫	消化器疾患 最新の治療	南江堂	大阪	2009	291-294

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akuta N, <u>Suzuki E</u> , Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.	Hepatology	46	1357-64	2007
Arase Y, Ikeda K, <u>Suzuki E</u> , Suzuki Y, Saitou S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.	Long-Term outcome after interferon therapy in elderly patients with chronic hepatitis C.	Intervirolgy	50	16-23	2007
Akuta N, <u>Suzuki E</u> , Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.	J Hepatol	46	403-10	2007

Arase Y, <u>Suzuki F</u> , Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Sezaki H, Sato J, Kobayashi M, Ikeda K, Kumada H.	Long-Term presence of HBV in the sera of chronic hepatitis b patients with HBsAg Seroclearance.	Intervirolgy	50	161-65	2007
Hosaka T, <u>Suzuki F</u> , Suzuki Y, Saitoh S, Kobayashi M, Someya T, Sezaki H,Akuta N, Arase Y, Ikeda K, Kumada H.	Factors associated with the virological response of Lamivudineresistnt hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine.	J Gastroenterol	42	368-74	2007
Kawaoka T, <u>Suzuki F</u> , Akuta N, Suzuki Y, Arase Y, Sezaki H, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, Kumada H.	Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection.	J Gastroenterol	42	395-401	2007
<u>Suzuki F</u> , Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	Selection of a virus strain resistant to entecavir in a nucleoside-naïve patient with hepatitis B of genotype H.	J Clin Virol	39	149-52	2007
Arase Y, Ikeda K, <u>Suzuki F</u> , Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.	Prolonged-Interferon therapy reduce hepatocarcinogenesis in aged-patients with chronic hepatitis C.	J Med Virol	79	1095-1102	2007
Matsumoto A, <u>Suzuki F</u> , Kobayashi M, Kumada H.	Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy.	Hepatol Res	37	661-66	2007

<u>Suzuki F</u> , Kumada H.	Interferon and lamivudine monotherapy on chronic hepatitis B in Japan.	Hepato Res	37	S42-S46	2007
Sezaki H, <u>Suzuki F</u> , Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load.	Hepato Res	37	787-92	2007
Hasegawa E, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, <u>Suzuki F</u> , Suzuki Y, Arase Y, Ikeda K, Kumada H.	Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2.	Hepato Res	37	793-800	2007
Kobayashi M, <u>Suzuki F</u> , Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Miyakawa Y, Kumada H.	Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine.	J Med Virol	79	1472-77	2007
Akuta N, <u>Suzuki F</u> , Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.	J Med Virol	79	1686-95	2007
Akuta N, <u>Suzuki F</u> , Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.	Intervirology	50	361-68	2007

Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Suzuki E, Kumada H, Chayama K.	Successful treatment of an Entecavir-resistant hepatitis B virus variant.	J Med Virol	79	1811-17	2007
Chihara E, Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.	Prolonged Hepatitis after acute infection with genotype H hepatitis B virus.	Int Med	46	1847-51	2007
Kawamura Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Arase Y, Kumada H.	Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.	Am J Med	120	1034-41	2007
Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Substitution of Amino Acid 70 in the Hepatitis C Virus Core Region of Genotype 1b Is an Important Predictor of Elevated Alpha-Fetoprotein in Patients Without Hepatocellular Carcinoma.	J Med Virol	80	1354-1362	2008
Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Efficacy of Low-Dose Intermittent Interferon-Alpha Monotherapy in Patients Infected With Hepatitis C Virus Genotype 1b Who Were Predicted or Failed to Respond to Pegylated Interferon Plus Ribavirin Combination Therapy.	J Med Virol	80	1363-1369	2008

Arase Y, <u>Suzuki F</u> , Sezaki H, Kawamura Y, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Yatsuji H, Hirakawa M, Kobayashi M, Ikeda K, Kumada H.	Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C.	Intervirolgy	51	1-6	2008
Arase Y, <u>Suzuki F</u> , Sezaki H, Kawamura Y, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Yatsuji H, Kobayashi M, Saitoh S, Ikeda K, Kumada H.	The Efficacy of Short-term Interferon-beta Therapy for Type C Cirrhotic Patients with Genotype 2a and Low Virus Load.	Intl Med	47	1085-10 90	2008
Arase Y, <u>Suzuki F</u> , Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Akuta N, Hosaka T, Yatsuji H, Ikeda K, Kobayashi M, Kumada H.	Suitable Treatment Period in patients with Virological Response during Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C.	Int Med	47	1301-13 07	2008
Arase Y, <u>Suzuki F</u> , Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Ikeda K, Kumada H.	Prolonged-Efficacy of Bisphosphonate in Postmenopausal Women With Osteoporosis and Chronic Liver Disease.	J Med Virol	80	1302-13 07	2008
Arase Y, <u>Suzuki F</u> , Suzuki Y, Akuta N, Sezaki H, Kobayashi M, Kawamura Y, Yatsuji H, Hosaka T, Saitoh S, Ikeda K, Kumada H.	Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses.	Hepatol Res	38	877-885	2008

Hirakawa M, Ikeda K, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Saitoh S, Arase Y, Kumada H.	New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle.	Liver Int	28(2)	214-219	2008
Kobayashi M, Ikeda K, Arase Y, Suzuki Y, <u>Suzuki E</u> , Akuta N, Hosaka T, Murashima N, Saitoh S, Someya T, Tsubota A, Kumada H.	Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus.	J Gastroenterol	43	63-70	2008
Kawamura Y, Arase Y, Ikeda K, <u>Suzuki F</u> , Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Kumada H.	The Efficacy of Short-term Interferon-beta Therapy for Chronic Hepatitis C Patients with Low Viurs Load.	Int Med	47	355-360	2008
<u>Suzuki F</u> , Suzuki Y, Akuta N, Yatsuji H, Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	Changes in viral loads of lamivudine-resistant mutants during entecavir therapy.	Hepatol Res	38	132-140	2008
<u>Suzuki F</u> , Toyoda J, Katano Y, Sata M, Moriyama M, Imazaki F, Kage M, Seriu T, Omata M, Kumada H.	Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: Randomized controlled trial in Japanese patients.	J Gastroenterol Hepatol	29(9)	1-7	2008

Yatsuji H, <u>Suzuki</u> E, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H.	Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamibudine combination therapy: Two-year follow-up.	J Hepatol	48	923-931	2008
Hirakawa M, Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki</u> E, Suzuki Y, Kumada H.	Hepatocarcinogenesis Following HCV RNA Eradication by Interferon in Chronic Hepatitis Patients.	Int Med	47	1637-1643	2008
Katamura Y, <u>Suzuki</u> E, Akuta N, Sezaki H, Yatsuji H, Nomura H, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Natural human interferon β plus rivavirin combination therapy in Japanese patients infected with hepatitis C virus and high viral load.	Int Med	47	1827-2834	2008
Saneto H, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, <u>Suzuki</u> E, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Clinicopathological features, background liver disease and survival analysis of HCV-positive patients with hepatocellular carcinoma: Differences between young and elderly patients.	J Gastroenterol	43	975-81	2008

Kobayashi M, Ikeda K, Arase Y, <u>Suzuki F</u> , Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H.	Change of Hepatitis B Virus Genotypes in Acute and Chronic Infections in Japan.	J Med Virol	80	1880-1884	2008
Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Kumada H.	Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis.	J Gastroenterol Hepatol	23	1739-46	2008
Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Saitoh S, Arase Y, Kumada H.	High serum Alpha Fetoprotein and Des-gamma-Carboxy Prothrombin Level Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular carcinoma.	Cancer	115	571-580	2009
<u>Suzuki E</u> , Miyakoshi H, Kobayashi M, Kumada H.	Correlation between Serum Hepatitis B Virus Core-Related Antigen and Intrahepatic Covalently Closed Circular DNA in Chronic Hepatitis B Patients.	J Med Virol	81	27-33	2009
Sezaki H, <u>Suzuki E</u> , Akuta N, Yatsuji H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with C virus genotype 1b in high viral loads.	Intervirology	52	43-48	2009
Kawamura Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin.	Hepatol Res	39	346-354	2009

Arase Y, <u>Suzuki F</u> , Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.	Hepatology	49	739-744	2009
Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, Akuta N, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study.	J Viral Hepat	16	437-443	2009
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: Amino acid substitutions in HCV core region as predictor of sustained virological response.	J Med Virol	81	452-458	2009
Akuta N, <u>Suzuki F</u> , Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil	Intervirol	51(6)	385-393	2009
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.	J Med Virol	81	1032-1039	2009

Arase Y, <u>Suzuki F</u> , Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Combination Therapy of Peginterferon and Ribavirin for Hepatitis C Patients with Genotype 1b and Low-virus Load.	Int Med	48	253-258	2009
Arase Y, <u>Suzuki F</u> , Ikeda K, Kumada H, Tsuji H, Kobayashi T.	Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease.	J Gastroenterol	44(10)	1064-1070	2009
Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Kumada H.	Significance and necessities of interferon therapy in elderly patients with hepatitis C virus-related chronic liver disease.	Am J Med	122	479-486	2009
Sezaki H, <u>Suzuki F</u> , Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	Poor Response to Pegylated Interferon and Ribavirin in Aged Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads.	Dig Dis Sci	54	1317-1324	2009
<u>Suzuki F</u> , Kobayashi M, Kumada H, Miyakoshi H.	Correlation Between Serum Hepatitis B Virus Core-Related Antigen and Intrahepatic Covalently Closed Circular DNA Chronic Hepatitis B Patients.	J Med Virol	81	27-33	2009
Hosaka T, Ikeda K, Kobayashi M, Kawamura Y, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma.	Liver Int	29	736-742	2009